Recce Pharmaceuticals (ASX: $RCE) receives HREC approval for Phase II clinical trial

Recce Pharmaceuticals Ltd (ASX: $RCE) has received Human Research Ethics Committee (HREC) approval to commence a Phase II clinical trial assessing RECCE® 327 (R327) as a topical, broad-spectrum gel applied to Acute Bacterial Skin and Skin Structure Infections (ABSSSI). The trial aims to provide critical data on the gel's effectiveness in treating a broad range of ABSSSI indications, including Diabetic Foot Infections (DFI), necrotizing fasciitis, post operative wound infections, and more.

Recce Pharmaceuticals CEO, James Graham, on HREC approval for Phase II clinical trial

Obtaining HREC approval marks another significant milestone for Recce and the clinicians striving to discover an effective treatment for ABSSSIs. This accomplishment highlights Recce's history of successful HREC approvals and underscores the dedication of our clinical and research team as we advance our topical treatment programs.

Recce Pharmaceuticals poised to address unmet medical needs in ABSSSI landscape

Recce Pharmaceuticals Ltd (ASX: $RCE) has received approval to centralise and broaden RECCE® 327 gel clinical trials for Acute Bacterial Skin and Skin Structure Infections (ABSSSI). The Phase II clinical trial aims to assess the gel's efficacy in treating a broad range of ABSSSI indications, including Diabetic Foot Infections (DFI), necrotizing fasciitis, and post operative wound infections. The company's CEO, James Graham, emphasized the significance of obtaining HREC approval, marking a significant milestone in their pursuit of effective treatments for ABSSSIs. With the global ABSSSI treatment market projected to reach $26B USD by 2032, Recce Pharmaceuticals is well-positioned to address unmet medical needs in the ABSSSI landscape.